Feature | TCT | November 09, 2017

TCT 2017 Late-breaking Clinical Trial Presentations

TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.

November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has selected 12 late-breaking clinical trials and 16 first report Investigations that are guaranteed to impact patient care and future directions in cardiovascular technologies.

Monday, October 30 - Main Arena I

Late-Breaking Clinical Trials 1

• CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock. Presenter is Holger Thiele.

• EXCEL QOL: Quality of Life After PCI vs. CABG in Left Main Coronary Artery Disease. Presenter is Suzanne J. Baron.

• DKCRUSH-V: A Randomized Trial of Double Kissing Crush vs. Provisional Stenting for Treatment of Distal Left Main Bifurcation Lesions. Presenter is Shao-Liang Chen.

First Report Investigations 1

• HREVS: A Randomized Trial of PCI vs. CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease. Presenter is Vladimir Ganyukov.

• HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-Based DES With a Luminal CD34+ Antibody Coating vs. a Durable Polymer-Based DES in Patients With Coronary Artery Disease. Presenter is Shigeru Saito.

• DARE: A Randomized Trial of a Drug-Eluting Balloon vs. a Metallic DES in Patients With Coronary Artery In-Stent Restenosis. Presenter is Jose P.S. Henriques.

• VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque. Presenter is Kiyoshi Hibi.

Tuesday, October 31, 2017 - Main Arena II

Late-Breaking Clinical Trials 2: Co-sponsored by the Lancet

• ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs. a Metallic DES in Patients With Coronary Artery Disease. Presented by Gregg W. Stone.

• ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease. Presented by Stephen G. Ellis.

• PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis. Presented by David J. Cohen.

First Report Investigations 2

• ABSORB II: 4-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease. Presented by Bernard R. Chevalier.

• CrossBoss First: A Randomized Trial of Antegrade Dissection and Re-entry vs Standard Wire Escalation for Crossing Coronary Artery Chronic Total Occlusions. Presented by Emmanouil S. Brilakis.

• REVASC: A Randomized Trial to Assess Recovery of Left Ventricular Function After PCI of Coronary Artery Chronic Total Occlusions. Presented by Kambis Mashayekhi.

• FAVOR II China: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio (QFR) FFR-Angiography in Patients With Coronary Artery Disease. Presented by Bo Xu.

• FAVOR II Europe Japan: Diagnostic Accuracy of the Angiographic Quantitative Flow Ratio (QFR) FFR-Angiography in Patients With Coronary Artery Disease. Presented by Jelmer Westra.

Wednesday, November 1, 2017 - Main Arena III

Late-Breaking Clinical Trial 3: Co-sponsored by the Journal of the American Medical Association

• SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs. a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years. Presented by Olivier Varenne.

• DAPT STEMI: A Randomized Trial of 6-Month vs. 12-Month DAPT After DES Implantation in STEMI. Presented by Elvin Kedhi.

• REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating in Patients With ACS. Presented by Harry Suryapranata.

First Report Investigations 3

• MITRAL: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings. Presented by Mayra Guerrero.

• INTREPID: 30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation. Presented by Paul Sorajja.

• TENDYNE: 1-Year Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation. Presented by David W.M. Muller.

• TRACER: 6-Month Outcomes of Transcatheter MV Neochordal Repair with the Harpoon System in Patients With Severe Primary Mitral Regurgitation. Presented by James S. Gammie.

• MAVERIC: 6-Month Outcomes of Transcatheter MV Repair in Patients With Severe Secondary Mitral Regurgitation. Presented by Stephen G. Worthley.

Thursday, November 2, 2017 - Main Arena IV

Late-Breaking Clinical Trials 4

• PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure (LAA) vs. Medical Therapy in Patients With Non-Valvular Atrial Fibrillation. Presented by Vivek Y. Reddy.

• ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease. Presented by Rasha Al-Lamee.

• FAME 2: 3-Year Clinical and Cost-Effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease. Presented by William F. Fearon.

First Report Investigations 4

• TRI-REPAIR: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation. Presented by Georg Nickenig.

• FORMA: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation. Presented by Susheel K. Kodali.

Other Studies, Videos and Articles From TCT 2017

VIDEO: What Went Wrong With the Absorb Stent? – discussion on the Absorb trials at TCT 2017 with Ajay Kirtane, M.D.

Current State of Bioresorbable Stent Technology

Positive, Sustained Improvements Seen at One Year in SCOUT I With Transcatheter Tricuspid Repair

VIDEO: Transcatheter Mitral Valve Implantation in Practice and Technologies in Development

VIDEO: The Role and Responsibilities of the Cath Lab Manager

VIDEO: New Frontiers in Radial Access

VIDEO: TAVR For Asymptomatic Severe Aortic Stenosis – with Philippe Genereux, M.D.

SURTAVI and FORWARD Studies Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Patients

VIDEO: Overview of the National Cardiogenic Shock Initiative — with William W. O’Neill, M.D.

Supersaturated Oxygen Therapy Reduces Infarct Size for High-Risk Stented AMI Patients

VIDEO: How Transcatheter PFO Closure Can Reduce Cryptogenic Stroke — with John Rhodes, M.D.

VIDEO: Update of Mitral Valve Repair and Replacement Technologies — with Ted Feldman, M.D.

4C Medical's Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition

VIDEO: Cath Lab of the Future Cardiovascular Technologies to Watch — with Juan Granada, M.D.

VIDEO: Converting to Bundled Payments for PCI — with Peter Duffy, M.D.

For more information: www.crf.org/tct/agenda/2017-late-breaking-trials-and-first-report-investigations

Links to Late-breaking Trials at Other Meetings:

SCAI 2017 Late-Breaking Clinical Trial Presentations

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

ACC 2017 Late-Breaking Trials

TCT 2016 Late-breaking Trials and First Reports

Log in or register to post comments

Related Content

News | Cath Lab

New Study Looks at High Health Risk for Early Career Cath Lab Staff

May 1, 2025 – Analyses from the (Ergonomics in the Cardiac Catheterization Laboratory (ERGO-CATH) study show the ...

May 01, 2025

GE Healthcare AltiX AI.i

News | Cath Lab

GE HealthCare Expands Invasive Cardiology Product Offerings

March 17, 2025 — GE HealthCare recently launched the AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab. The AltiX AI ...

March 17, 2025

Jason McCarthy, Ph.D., associate professor of biomedical research and translational medicine at MMRI

News | Cath Lab

MMRI Publishes Breakthrough Study Detailing a Novel Approach to Minimize Damage After a Heart Attack

December 20, 2023 — Jason R. McCarthy, Ph.D., associate professor of biomedical research and translational medicine and ...

December 20, 2023

WATCH TAVR trial presented at the Transcatheter Cardiovascular Therapeutics annual conference

News | Cath Lab

iFR and FFR are Equally Safe to Diagnose and Treat Heart Disease According to Largest-ever Analysis of New Real-world, Long-term Data

October 26, 2023 — Royal Philips, a global leader in health technology, announced the latest results demonstrating the ...

October 26, 2023

Clinical research validates utility of IVL in complex nodular and eccentric calcium

News | Cath Lab

New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

October 25, 2023 — Shockwave Medical, Inc., a pioneer in the development and commercialization of transformational ...

October 25, 2023

Published late-breaking clinical data presented at TCT 2023

News | Cath Lab

Philips Showcases Latest Medical Innovations and Solutions for Patients with Cardiovascular Disease TCT23

October 20, 2023 — Over the coming days, Philips will be presenting its latest solutions in cardiology and new late ...

October 20, 2023

Building on the award-winning Allia platform for image guided therapies, GE HealthCare's new Allia IGS Pulse was designed to improve workflow for the diagnosis and treatment of cardiovascular diseases in interventional cardiology. (Photo: Business Wire)

News | Cath Lab

GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

October 16, 2023 — GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest ...

October 16, 2023

Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, announced the first U.S. installation of a Trinias SCORE Opera C12 (ceiling mounted cutting edge angiography system) at Beaufort Memorial Hospital (Beaufort, SC).

News | Cath Lab

Shimadzu Medical Systems USA Installs First Trinias Score Opera Cardiac Catheterization Lab in the US

October 16, 2023 — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, announced the first U.S ...

October 16, 2023

University Hospitals Harrington Heart & Vascular Institute first to adopt technology in U.S.

News | Cath Lab

New Study Confirms HeartFlow FFRCT Leads to Improved Patient Outcomes

September 13, 2023 — A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart ...

September 13, 2023

the U.S Food and Drug Administration (FDA) has cleared the QuikClot Control+ Hemostatic Device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a sternotomy

News | Cath Lab

Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+ Hemostatic Device Usage in Cardiac Surgical Procedures

August 2, 2023 — Teleflex Incorporated, a leading global provider of medical technologies, announced the U.S Food and ...

August 02, 2023

© Copyright Wainscot Media. All Rights Reserved.